

Our ref: FOI 492

20th April 2021

FOI Response 492

Q1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

• Abatacept [Orencia]	58
• Adalimumab [Humira]	46
• Adalimumab Biosimilars	339
• Apremilast [Otezla]	0
• Baricitinib [Olumiant]	34
• Certolizumab [Cimzia]	66
• Etanercept [Enbrel]	22
• Etanercept Biosimilars	167

Q1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

• Filgotinib [Jyseleca]	0
• Golimumab [Simponi]	85
• Infliximab [Remicade]	<5
• Infliximab Biosimilars	26
• Ixekizumab [Taltz]	<5
• Rituximab [MabThera]	35
• Rituximab Biosimilars	120
• Sarilumab [Kevzara]	<5
• Secukinumab [Cosentyx]	97
• Tocilizumab [Ro Actemra]	29
• Tofacitinib [Xeljanz]	21
• Upadacitinib [Rinvoq]	0
• Ustekinumab [Stelara]	<5

Part 3 - Q2. Could you please provide the numbers of patients treated for Psoriatic Arthritis ONLY in the last 3 months with the following drugs.

• Abatacept [Orencia]	<5
• Adalimumab [Humira]	20
• Adalimumab Biosimilars	114
• Apremilast [Otezla]	0
• Certolizumab [Cimzia]	30
• Etanercept [Enbrel]	5
• Etanercept Biosimilars	50
• Golimumab [Simponi]	28
• Guselkumab [Tremfya]	0
• Infliximab [Remicade]	0
• Infliximab Biosimilars	9
• Ixekizumab [Taltz]	<5
• Secukinumab [Cosentyx]	52
• Tofacitinib [Xeljanz]	6
• Ustekinumab [Stelara]	<5

Please note less than 5 values are indicated accordingly. The Trust has a legal duty to protect patient confidentiality and of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the level of media reporting in regards to this type of treatment. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the redacted information from disclosure. The Trust does not consider the disclosure of the redacted information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018.

Contact: FOI.team@southerntrust.hscni.net